4RRS
8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors
4RRS の概要
| エントリーDOI | 10.2210/pdb4rrs/pdb |
| 関連するPDBエントリー | 4R5N 4RRN 4RRO |
| 分子名称 | Beta-secretase 1, NICKEL (II) ION, (4R,4a'R,10a'S)-8'-(2-fluoropyridin-3-yl)-4a'-methyl-3',4',4a',10a'-tetrahydro-2'H-spiro[1,3-oxazole-4,10'-pyrano[3,2-b]chromen]-2-amine, ... (4 entities in total) |
| 機能のキーワード | aspartyl protease, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor |
| 由来する生物種 | Homo sapiens (human) |
| 細胞内の位置 | Membrane; Single-pass type I membrane protein: P56817 |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 45873.20 |
| 構造登録者 | Thomas, A.A.,Hunt, K.W.,Newhouse, B.,Watts, R.J.,Liu, X.,Vigers, G.P.A.,Smith, D.,Rhodes, S.P.,Brown, K.D.,Otten, J.N.,Burkard, M.,Cox, A.A.,Geck Do, M.K.,Dutcher, D.,Rana, S.,DeLisle, R.K.,Regal, K.,Wright, A.D.,Groneberg, R.,Liao, J.,Scearce-Levie, K.,Siu, M.,Purkey, H.E.,Lyssikatos, J.P. (登録日: 2014-11-06, 公開日: 2014-12-03, 最終更新日: 2024-10-30) |
| 主引用文献 | Thomas, A.A.,Hunt, K.W.,Newhouse, B.,Watts, R.J.,Liu, X.,Vigers, G.,Smith, D.,Rhodes, S.P.,Brown, K.D.,Otten, J.N.,Burkard, M.,Cox, A.A.,Geck Do, M.K.,Dutcher, D.,Rana, S.,DeLisle, R.K.,Regal, K.,Wright, A.D.,Groneberg, R.,Liao, J.,Scearce-Levie, K.,Siu, M.,Purkey, H.E.,Lyssikatos, J.P. 8-Tetrahydropyran-2-yl Chromans: Highly Selective Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors. J.Med.Chem., 57:10112-10129, 2014 Cited by PubMed Abstract: A series of 2,3,4,4a,10,10a-hexahydropyrano[3,2-b]chromene analogs was developed that demonstrated high selectivity (>2000-fold) for BACE1 vs Cathepsin D (CatD). Three different Asp-binding moieties were examined: spirocyclic acyl guanidines, aminooxazolines, and aminothiazolines in order to modulate potency, selectivity, efflux, and permeability. Guided by structure based design, changes to P2' and P3 moieties were explored. A conformationally restricted P2' methyl group provided inhibitors with excellent cell potency (37-137 nM) and selectivity (435 to >2000-fold) for BACE1 vs CatD. These efforts lead to compound 59, which demonstrated a 69% reduction in rat CSF Aβ1-40 at 60 mg/kg (PO). PubMed: 25411915DOI: 10.1021/jm5015132 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.8 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






